Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Short Interest Up 9.1% in October

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 3,240,000 shares, an increase of 9.1% from the September 30th total of 2,970,000 shares. Based on an average trading volume of 2,250,000 shares, the short-interest ratio is presently 1.4 days. Approximately 1.5% of the shares of the company are sold short.

Institutional investors and hedge funds have recently made changes to their positions in the company. Nuveen Asset Management LLC boosted its holdings in Alexion Pharmaceuticals by 57,650.8% during the second quarter. Nuveen Asset Management LLC now owns 3,637,144 shares of the biopharmaceutical company’s stock worth $476,393,000 after buying an additional 3,630,846 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Alexion Pharmaceuticals by 104.9% in the second quarter. Renaissance Technologies LLC now owns 1,642,542 shares of the biopharmaceutical company’s stock valued at $215,140,000 after buying an additional 840,742 shares in the last quarter. Swedbank lifted its position in shares of Alexion Pharmaceuticals by 95.5% during the 2nd quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock valued at $187,222,000 after acquiring an additional 698,096 shares during the period. Prudential Financial Inc. lifted its position in shares of Alexion Pharmaceuticals by 87.0% during the 2nd quarter. Prudential Financial Inc. now owns 1,180,067 shares of the biopharmaceutical company’s stock valued at $154,565,000 after acquiring an additional 549,063 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Alexion Pharmaceuticals by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 16,649,126 shares of the biopharmaceutical company’s stock valued at $2,180,703,000 after acquiring an additional 211,960 shares during the period. Institutional investors and hedge funds own 94.56% of the company’s stock.

Shares of NASDAQ ALXN opened at $108.37 on Monday. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.45. The stock has a fifty day moving average price of $102.94 and a 200 day moving average price of $115.01. Alexion Pharmaceuticals has a 1-year low of $92.56 and a 1-year high of $141.86. The company has a market cap of $23.43 billion, a PE ratio of 15.28, a P/E/G ratio of 1.01 and a beta of 1.65.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 23rd. The biopharmaceutical company reported $2.79 EPS for the quarter, beating analysts’ consensus estimates of $2.47 by $0.32. The company had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.24 billion. Alexion Pharmaceuticals had a return on equity of 21.21% and a net margin of 31.05%. Alexion Pharmaceuticals’s quarterly revenue was up 23.0% compared to the same quarter last year. During the same quarter last year, the company earned $2.02 earnings per share. Analysts anticipate that Alexion Pharmaceuticals will post 9.39 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on ALXN. Bank of America began coverage on shares of Alexion Pharmaceuticals in a research report on Thursday, October 17th. They set a “buy” rating on the stock. SunTrust Banks assumed coverage on Alexion Pharmaceuticals in a report on Tuesday, November 12th. They set a “buy” rating and a $125.00 price target for the company. JPMorgan Chase & Co. assumed coverage on Alexion Pharmaceuticals in a report on Wednesday, July 31st. They set an “overweight” rating and a $172.00 price target for the company. Robert W. Baird set a $165.00 price target on Alexion Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, August 30th. Finally, Morgan Stanley decreased their price target on Alexion Pharmaceuticals from $177.00 to $170.00 and set an “overweight” rating for the company in a report on Friday, October 11th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and seventeen have assigned a buy rating to the company. Alexion Pharmaceuticals has an average rating of “Buy” and a consensus target price of $156.47.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

Featured Article: What is a Real Estate Investment Trust (REIT)?

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.